http://www.biohealthcapital.com Advancing Science. Accelerating Innovation. Fri, 13 Sep 2024 18:14:06 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.15 http://www.biohealthcapital.com/news/united-states-pharmacopeia-ceo-ron-piervincenzi-ph-d-returns-to-biotalk/ http://www.biohealthcapital.com/?p=3968 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 14 Feb 2022 14:17:42 +0000 Ron Piervincenzi, Ph.D., CEO of United States Pharmacopeia, sits down with host, Rich Bendis, to discuss USP’s growth since his last visit, the nature of their organization, and plans on...]]> http://www.biohealthcapital.com/news/childrens-national-uses-hifu-to-perform-first-ever-non-invasive-brain-tumor-surgery/ http://www.biohealthcapital.com/?p=3971 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Wed, 09 Feb 2022 14:19:14 +0000 Children’s National Hospital successfully performed the first-ever high-intensity focused ultrasound (HIFU) surgery on a pediatric patient with neurofibromatosis (NF). This is the youngest patient to undergo HIFU treatment in the...]]> http://www.biohealthcapital.com/news/maxcyte-signs-strategic-platform-license-with-intima-bioscience-to-advance-tumor-infiltrating-lymphocytes-programs/ http://www.biohealthcapital.com/?p=3981 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 07 Feb 2022 14:24:02 +0000 Intima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidates NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE...]]> http://www.biohealthcapital.com/news/american-gene-technologies-hiv-clinical-trial-shows-blood-markers-of-efficacy-in-two-more-patients/ http://www.biohealthcapital.com/?p=3979 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 07 Feb 2022 14:22:54 +0000 ROCKVILLE, MD. (PRWEB)  FEBRUARY 02, 2022 Data from a Total of Five Patients Demonstrates Critical Markers of the Company’s HIV Cure Gene & Cell Therapy American Gene Technologies (AGT), a...]]> http://www.biohealthcapital.com/news/geoffrey-lynn-co-founder-avedia-svp-synthetic-immunotherapies-vaccitech-joins-biotalk/ http://www.biohealthcapital.com/?p=3973 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 07 Feb 2022 14:20:31 +0000 Geoffrey Lynn, SVP, Synthetic Immunotherapies, Vaccitech, visits Rich Bendis to discuss his career from NIH, to CEO of Avidea, to their merger with Vaccitech. Listen now via Apple https://apple.co/3GztBZg, Google https://bit.ly/3gAfHvn, Spotify https://spoti.fi/3GBiaAm,...]]> http://www.biohealthcapital.com/news/how-johns-hopkins-inventors-vision-for-early-cancer-detection-got-a-2-1b-boost/ http://www.biohealthcapital.com/?p=3976 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Wed, 02 Feb 2022 14:21:25 +0000 Johns Hopkins researchers Nickolas Papadopoulos, Ken Kinzler and Bert Vogelstein have spent their careers working on ways not just to treat cancer but to detect it before it becomes a threat. The goal: a blood...]]> http://www.biohealthcapital.com/news/biobuzz-trends-in-talent-acquisition-covid-edition/ http://www.biohealthcapital.com/?p=3983 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 31 Jan 2022 14:25:12 +0000 The pandemic, now approaching year three in full force, has impacted nearly every facet of the life sciences’ job market. A talent shortage existed pre-pandemic and has only accelerated since then. For...]]> http://www.biohealthcapital.com/news/vaccitech-ceo-bill-enright-joins-rich-bendis-on-first-biotalk-of-2022/ http://www.biohealthcapital.com/?p=3987 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Tue, 25 Jan 2022 14:26:58 +0000 Bill visits BioTalk to talk about being a serial entrepreneur, biotech executive, and their recent acquisition of Avidea Technologies. Listen now via Apple https://apple.co/3fTySQM, Google https://bit.ly/3KDPMkh, Spotify https://spoti.fi/3rI7UB3, Amazon https://amzn.to/33DwOtH, or TuneIn https://bit.ly/3fS8C9f. William “Bill”...]]> http://www.biohealthcapital.com/news/cartesian-therapeutics-doses-patient-with-first-allogeneic-rna-cell-therapy-for-multiple-myeloma/ http://www.biohealthcapital.com/?p=3985 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Tue, 25 Jan 2022 14:26:10 +0000 Descartes-25 engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment Product generated from Company’s Part 1271-compliant Master Cell Bank of human umbilical cord Mesenchymal Stem...]]> http://www.biohealthcapital.com/news/orgenesis-and-johns-hopkins-university-expand-pocare-in-maryland-through-creation-of-the-maryland-center-for-cell-therapy-manufacturing/ http://www.biohealthcapital.com/?p=3990 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Tue, 18 Jan 2022 14:28:18 +0000 Center will expand Orgenesis’ Point of Care (POCare) Platform Capabilities in Maryland GERMANTOWN, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company...]]> http://www.biohealthcapital.com/news/hibiscus-bioventures-partners-with-the-barbara-ann-karmanos-cancer-institute-to-advance-translational-cancer-research/ http://www.biohealthcapital.com/?p=3955 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 10 Jan 2022 14:13:11 +0000 – Partnership aims to drive innovation and clinical development of novel therapeutics for cancer treatment – ROCKVILLE, Md.–(BUSINESS WIRE)–Hibiscus BioVentures, a firm committed to building patient-focused companies around transformative technologies,...]]> http://www.biohealthcapital.com/news/regenxbio-announces-initiation-of-second-pivotal-trial/ http://www.biohealthcapital.com/?p=3953 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 10 Jan 2022 14:12:14 +0000 OCKVILLE, Md., Jan. 10, 2022 /PRNewswire/ — ASCENTTM, a Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada Pivotal...]]> http://www.biohealthcapital.com/uncategorized/a-regional-economic-development-strategy-and-why-commercial-real-estate-should-care/ http://www.biohealthcapital.com/?p=3958 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Fri, 07 Jan 2022 14:14:20 +0000 The U.S. Economic Development Administration announced last month the winners of $500,000 planning grants to 60 jurisdictions across the country for the $1 billion Build Back Better Regional Challenge. Winners...]]> http://www.biohealthcapital.com/news/horizon-therapeutics-plc-announces-significant-expansion-of-east-coast-research-and-development-and-technical-operations-capability/ http://www.biohealthcapital.com/?p=3961 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Thu, 06 Jan 2022 14:15:16 +0000 DUBLIN–(BUSINESS WIRE)–Jan. 6, 2022– Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the...]]> http://www.biohealthcapital.com/news/biobuzz-charlottesvilles-molecular-biologicals-is-changing-the-game-in-wound-care/ http://www.biohealthcapital.com/?p=3950 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Wed, 05 Jan 2022 14:49:42 +0000 Imagine you’re working outside and accidentally cut your foot on a protruding stick you didn’t see. No big deal. You go inside and wash the wound, perhaps applying an antibiotic...]]> http://www.biohealthcapital.com/news/zalgen-labs-move-to-frederick-is-another-sign-of-the-biohealth-capital-regions-strengths/ http://www.biohealthcapital.com/?p=3947 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Tue, 04 Jan 2022 14:42:14 +0000 Maryland biotech company Zalgen Labs has moved to Frederick, illustrating the magnetism of the biotech hub for leaders like its own Dr. Luis Branco who want to capitalize on the new sense of collaboration the pandemic...]]> http://www.biohealthcapital.com/uncategorized/personal-genome-diagnostics-being-acquired-by-labcorp-for-450m/ http://www.biohealthcapital.com/?p=3963 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 27 Dec 2021 14:16:24 +0000 By Holden Wilen – Reporter December 23, 2021, 01:35pm EST Personal Genome Diagnostics has agreed to be acquired by one of the world’s largest life sciences companies in a deal...]]> http://www.biohealthcapital.com/news/american-gene-technologies-hiv-clinical-trial-demonstrates-blood-markers-of-efficacy/ http://www.biohealthcapital.com/?p=3965 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Wed, 22 Dec 2021 14:17:29 +0000 ROCKVILLE, MD. (PRWEB) DECEMBER 22, 2021 American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that it has reached two important milestones for its HIV cure program. All...]]> http://www.biohealthcapital.com/news/marylands-novavax-working-on-its-version-of-covid-19-vaccine-to-target-omicron-variant/ http://www.biohealthcapital.com/?p=3938 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Wed, 01 Dec 2021 14:14:12 +0000 GAITHERSBURG, Md. (7News) — The Omicron variant is quickly becoming a household name but the hope is that it won’t enter households here in the D.C. area. After what happened a few months...]]> http://www.biohealthcapital.com/news/ab-agri-has-partnered-with-marylands-intralytix-inc-to-explore-the-use-of-bacteriophages/ http://www.biohealthcapital.com/?p=3941 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Tue, 30 Nov 2021 14:15:08 +0000 Peterborough, 30 November 2021 Gut health could be boosted without reliance on antibiotics and other medicines Bacteriophages are natural and abundant Exploration aligns with AB Agri’s sustainability agenda for food...]]> http://www.biohealthcapital.com/news/biohealth-capital-region-spotlight-creative-bio-peptides-awarded-5-78-million-from-nih-to-develop-breakthrough-treatments-for-neuroinflammatory-neurodegenerative-indications/ http://www.biohealthcapital.com/?p=3936 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 29 Nov 2021 14:13:20 +0000 Creative Bio-Peptides, Inc., an emerging drug development company focused on the development of leading-edge multi-chemokine antagonist therapeutic peptides for neuroinflammatory/neurodegenerative conditions, has been awarded $5.8M in non-dilutive funding from three...]]> http://www.biohealthcapital.com/news/montgomery-county-hires-state-house-vet-to-coordinate-white-flint-biohub-proposal/ http://www.biohealthcapital.com/?p=3933 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 29 Nov 2021 14:10:33 +0000 Montgomery County failed in its bid lure Amazon, the e-commerce giant that opted to build its second headquarters in Arlington, Va. But top county officials have an alternate vision for...]]> http://www.biohealthcapital.com/news/immunomic-therapeutics-announces-collaboration-with-ioncologi/ http://www.biohealthcapital.com/?p=3926 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 29 Nov 2021 14:07:11 +0000 – Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors November 23, 2021 06:41 PM Eastern Standard Time ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology company...]]> http://www.biohealthcapital.com/news/supernus-pharmaceuticals-completes-acquisition-of-adamas-pharmaceuticals/ http://www.biohealthcapital.com/?p=3931 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Wed, 24 Nov 2021 14:09:11 +0000 November 24, 2021 at 9:12 AM EST Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flowROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it...]]> http://www.biohealthcapital.com/news/red-cell-forms-zephyr-ai-to-revolutionize-drug-discovery-and-precision-medicine/ http://www.biohealthcapital.com/?p=3928 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 22 Nov 2021 14:08:17 +0000 November 22, 2021 TYSONS, Va.–(BUSINESS WIRE)–Red Cell Partners (“Red Cell”), an investment and incubation firm that backs, builds, and scales technology-led companies in healthcare and defense, today announced the formation...]]> http://www.biohealthcapital.com/news/regenxbio-announces-orphan-drug-designation-granted-to-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy/ http://www.biohealthcapital.com/?p=3924 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 22 Nov 2021 14:06:18 +0000 ROCKVILLE, Md., Nov. 22, 2021 /PRNewswire/ — Potential one-time gene therapy for the treatment of Duchenne, includes a novel, optimized microdystrophin transgene and REGENXBIO’s proprietary NAV® AAV8 vector Commercial-scale cGMP material to be...]]> http://www.biohealthcapital.com/news/study-aiming-to-define-acute-traumatic-encephalopathy-ate-published-by-leading-neurology-journal/ http://www.biohealthcapital.com/?p=3922 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Fri, 19 Nov 2021 14:05:12 +0000 BrainBox HeadSmart II Study Investigators Aim to Provide Clinicians with First-Ever Biomarkers and other Functional measurements for Acute Traumatic Encephalopathy (ATE.) A clinical trial of multi-modal diagnostic/prognostic test, already underway, is...]]> http://www.biohealthcapital.com/uncategorized/tedco-generates-2-3-billion-in-economic-benefits-to-the-state-of-maryland-and-supports-10433-maryland-jobs-according-to-new-independent-study/ http://www.biohealthcapital.com/?p=3919 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Wed, 17 Nov 2021 14:03:50 +0000 COLUMBIA, Md., Nov. 17, 2021 /PRNewswire/ — TEDCO, Maryland’s economic engine for technology companies, announced today the findings of an independent study detailing the impact of TEDCO’s six core programs to the state of Maryland. Conducted by...]]> http://www.biohealthcapital.com/news/deka-biosciences-raises-usd-20-million-in-series-a-financing/ http://www.biohealthcapital.com/?p=3915 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Tue, 16 Nov 2021 14:01:37 +0000 GERMANTOWN, Md., Nov. 16, 2021 /PRNewswire/ — Maryland-based biotech company Deka Biosciences (“Deka”) today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate...]]> http://www.biohealthcapital.com/uncategorized/emmes-and-medgenome-launch-genomics-strategic-partnership-focused-on-advancing-rare-disease-research/ http://www.biohealthcapital.com/?p=3913 scott@delmarvagroup.com (admin) http://www.biohealthcapital.com/wp-content/uploads/2022/02/RichandRon-1024x583.jpg"/> Mon, 15 Nov 2021 14:00:48 +0000 ROCKVILLE, Md., Nov. 15, 2021 /PRNewswire/ — Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced a partnership with MedGenome...]]>